This disclosure relates to dermal treatment compositions, such as dermal fillers and tissue glues, and injectable compositions that incorporate one or more cationic steroidal antimicrobials (CSAs). The CSAs are incorporated into the dermal treatment compositions to provide effective antimicrobial, anti-inflammatory, analgesic, anti-swelling and/or tissue-healing properties. A treatment composition includes a component formed from a biologically compatible material suitable for injection into and/or application onto tissue at a treatment site. One or more CSA compounds are mixed with the biologically compatible material so that the one or more CSA compounds are incorporated within the composition, forming a reservoir of CSA compounds within the resulting bolus of the treatment composition after injection and/or application.

Methods for enhancing or accelerating osseointegration of an implant into bone marrow of a subject, the methods comprising increasing expression of peripheral clock neuronal PAS domain protein 2 (NPAS2) in the bone marrow, are provided. Expression of NPAS2 is increased by administration of a Npas2 modulating compound to the subject.

Provided herein are submucosal lifting compositions and methods of using same. The submucosal lifting agents of the disclosure include a polysaccharide, a polyol, and a colorant.

Medical devices such as stents, stent grafts, and balloon catheters include a coating layer applied over a modified exterior surface of the medical device. The modified exterior surface comprises an exterior surface of the medical device subjected to a surface modification that decreases a surface free energy of the exterior surface before application of the coating layer an exterior surface. The coating layer comprises a hydrophobic therapeutic agent and at least one additive. The modified exterior surface may affect the release kinetics of the drug from the device, the crystallinity of the drug layer, the surface morphology of the coating and particle shape, or the particle size of drug of a therapeutic layer in the coating layer. For example, the effects caused by the modified exterior surface may increase the retention time and amount of therapeutic agent in tissue.

The present invention relates to a coating composition for an in-vivo implantable prosthesis including a photoinitiator, a crosslinking agent, and a phosphorylcholine (pc) monomer having an acrylate group, a method of coating an in-vivo implantable prosthesis using the coating composition, and a cosmetic prosthesis coated with the crosslinked polyphosphorylcholine.

An in-vivo implantable prosthesis coated with crosslinked polyphosphorylcholine may be manufactured by a simple method of applying a coating composition including a photoinitiator, a crosslinking agent, and a phosphorylcholine (pc) monomer having an acrylate group according to the present invention, and then irradiating uv rays. The crosslinked polyphosphorylcholine coating may provide hydrophilicity for the surface and may also remarkably reduce adsorption of proteins and fibroblasts, which may cause side effects such as capsular contracture. Further, the coating has strong enough not to peel off even under stimulation, and therefore, it is maintained under vigorous activity after implantation, thereby being usefully applied to the manufacture of an in-vivo implantable prosthesis with reduced side effects, such as breast prosthesis for cosmetic surgery.

Disclosed herein is a biomaterial and a method of use thereof for treating a condition. A biomaterial of the disclosure can be, for example, a surgical article. Implantation of a biomaterial disclosed herein into a subject can treat, for example, cancer.

Described herein are bisphosphonate oxazolidinone compounds, and conjugates and pharmaceutical formulations thereof, that can include a bisphosphonate and an oxazolidinone (or an oxazolidinone antimicrobial or antibiotic agent, substituent or derivative thereof), where the oxazolidinone can be releasably coupled to the bisphosphonate. Also provided herein are methods of making and methods of using the bisphosphonate oxazolidinone compounds, conjugates and pharmaceutical formulations thereof. Also provided herein are methods of use of the compounds, conjugates and formulations for treating a bone disease or for use in preparing a formulation for the treatment a bone disease.

Angioplasty balloons coated with at least one limus drug, which may be in crystalline form, optionally with at least one excipient, and methods for manufacturing such coated angioplasty balloons.

A pharmaceutical composition is described. The pharmaceutical composition includes a polymeric coating composition comprising polymeric nanoparticles dispersed within a polymeric matrix, wherein the polymeric nanoparticles include a first therapeutic agent and a second therapeutic agent. Implantable medical devices coated with the pharmaceutical composition, methods of coating an implantable medical device with the pharmaceutical composition, and methods of treating vascular disease using the pharmaceutical composition are also described.

The present invention provides materials and methods for forming an interface between an appliance and living tissue using a foamed elastomeric material which contacts the tissue or similar surfaces. The elastomeric material is in the form of a durable and washable material that, when applied to or implanted in living tissue or similar surfaces, displaces and flows in to non-conforming areas creating an air and/or water tight seal that substantially returns to an original shape when removed from the contact surface. The appliance may also include structural elements designed to optimize comfort, compliance and seal achieved through minimizing the pressure variation along the contact surface of the therapy device.